We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine.
Expertise
From patient-based disease models to novel therapeutic molecules.
Pipeline
Innovation holds the key. Our pipeline of drug discovery programs.
Partner with us
Initiate, codevelop or support our discovery programs.
Newsroom
Keep posted about
our latest developments
and achievements
Video: Ksilink x 2CRSI
Ksilink and 2CRSI – acting together to enable next generation medicine. Collaborating since more than 5 years with 2CRSI, Ksilink is honored to be now recognized as one of...
Job posting – Cell Biology Research Technician position in Early Discovery & Technology Development team (M/F)
A Cell Biology Research Technician position in Early Discovery & Technology Development team is available at Ksilink. To read the job offer in English, please click here To...
We are proud to announce the release of our new website!
We are happy to welcome you on our new website. We will keep you informed about news and activities around patient-based drug discovery. Come and visit us on www.ksilink.com !!
They trust us
“Patient-derived disease models used for phenotypic drug discovery purposes carry a huge potential. We strongly believe in Ksilink as a key player for effectively bridging the gap between scientific excellence and the pharma industry.”
Jacques Volckmann, Head of R&D, Sanofi, France
“Ksilink’s capacities to apply patient-derived disease models for high-throughput, high-content screening by using AI-driven deep learning computation is outstanding.”
Wolfram Zimmermann, CSO, Myriamed GmbH, Germany
“Bridging the gap between academic clinical research and industry is key to enable the precision medicine of tomorrow. We see big value in the ability of Ksilink to translate clinical expertise into treatment for diseases with high unmet medical need .”
Andreas Meyer-Lindenberg, Director and CEO, Central Institute of Mental Health, Germany
“Phenotypic screening using most authentic disease models is clearly paving the way towards next generation medicine. We strongly believe in Ksilink’s potential, allowing the generation of valuable first-in-class therapeutic molecules.”
Bert Klebl, Managing Director of Lead Discovery Center, Germany